What is the P/E ratio of Vysali Pharmaceuticals?

The latest standalone P/E ratio of Vysali Pharmaceuticals as of 01-Jan-1970 is 0.00.

What is the P/B ratio of Vysali Pharmaceuticals?

The latest standalone P/B ratio of Vysali Pharmaceuticals as of 01-Jan-1970 is -0.26.

What is the 52-week high and low of Vysali Pharmaceuticals?

The 52-week high of Vysali Pharmaceuticals is Rs. 0.00 and the 52-week low is Rs. 0.00.

Vysali Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Name: Vysali Pharmaceuticals
Brand: Vysali Pharmaceuticals

BSE: 524290 | NSE: | Pharmaceuticals & Drugs | Small Cap

Place order

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Vysali Pharma

Based on:

Data

M-Cap below 100cr DeciZen not available

Vysali Pharmaceuticals stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.00

Market Cap:

2.3 Cr.

52-wk low:

52-wk high:

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Vysali Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Jun'99	Jun'00	Sep'01	Mar'03	Mar'04	Mar'05	Mar'06	Jun'07	Mar'08	Mar'09	TTM
ROCE % ⓘ	7.5%	-13.9%	9.6%	-4.6%	-16.6%	-32.3%	-49.7%	-2.7%	-52.2%	-21.3%	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	15.8	12.9	11.8	12.7	8	7	5.1	8.1	4.8	1.2	1
Sales YoY Gr.	-	-18.2%	-9.2%	7.9%	-37.2%	-12.6%	-26.6%	58.7%	-41.3%	-75.4%	-
Adj EPS ⓘ	-1	-9.1	1.2	-3.1	-7.9	-9	-9.3	-0.9	-26.3	-5.9	-5.8
YoY Gr.	-	NA	NA	-352%	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	11.8	3.7	4.2	0.4	-7.2	-16.2	-25.5	17.2	2.4	-4.1	-16.2
Adj Net Profit ⓘ	-0.6	-4.9	0.7	-1.7	-4.3	-4.9	-5	-0.5	-14.3	-3.2	-3
Cash Flow from Ops. ⓘ	-2.3	-2.8	0.4	-2	-0.1	-0.4	-0.2	9.8	-1.9	0	-
Debt/CF from Ops. ⓘ	-5.7	-6.5	34.5	-7	-223.3	-57.7	-99	0.8	-8.9	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-25.1%	-31.9%	-38.8%	-75.4%
Adj EPS ⓘ	NA	NA	NA	NA
BVPSⓘ	-188.8%	NA	NA	-270.9%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Jun'99	Jun'00	Sep'01	Mar'03	Mar'04	Mar'05	Mar'06	Jun'07	Mar'08	Mar'09	TTM
Return on Equity % ⓘ	-7.7	-110.6	33.8	-154.3	244.5	77.2	44.5	54.7	-169.5	515.8	57.3
Op. Profit Mgn % ⓘ	16.5	-15	7.8	-4.5	-42.2	-64.1	-101.9	-3.9	-232.9	-159	-54.8
Net Profit Mgn % ⓘ	-3.5	-38.2	5.7	-13.3	-53.9	-70.5	-98.4	-5.8	-300.6	-272.2	-269.6
Debt to Equity ⓘ	2	8.9	6.1	64	-5.3	-2.4	-1.5	0.9	12.9	-6.2	-
Working Cap Days ⓘ	428	545	463	374	813	750	721	291	529	390	0
Cash Conv. Cycle ⓘ	343	450	371	310	695	634	591	214	389	-55	0

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Vysali Pharmaceuticals Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-5.8	-
TTM Sales (₹ Cr.)	1.2	-
BVPS (₹.) ⓘ	-16.2	-
Reserves (₹ Cr.) ⓘ	-14	-
P/BV ⓘ	-0.26	-
PE ⓘ	0.00	-

From the Market
52 Week Low / High (₹)	0.00 / 0.00
All Time Low / High (₹)	0.70 / 34.00
Market Cap (₹ Cr.)	2.3
Equity (₹ Cr.)	5.4
Face Value (₹)	10
Industry PE ⓘ	47.2

Management X-Ray of Vysali Pharma:

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Valuation of Vysali Pharma

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Vysali Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Jun'99	Jun'00	Sep'01	Mar'03	Mar'04	Mar'05	Mar'06	Jun'07	Mar'08	Mar'09
Sales	15.82	12.94	14.68	19.01	7.96	6.96	5.11	10.14	3.57	1.17
Operating Expenses ⓘ	13.20	14.88	13.54	19.86	11.32	11.42	10.32	10.54	11.87	3.03
Manufacturing Costs	4.13	3.07	3.45	4.56	2.26	1.64	2.01	3.25	1.32	0.30
Material Costs	3.97	7.17	5.84	8.58	4.24	6.90	2.95	4.01	4.71	0.52
Employee Cost	2.32	2.06	2.22	2.76	2	1.70	1.21	1.75	1.12	0.54
Other Costs ⓘ	2.78	2.57	2.04	3.96	2.83	1.18	4.15	1.53	4.72	1.66
Operating Profit ⓘ	2.61	-1.94	1.14	-0.85	-3.36	-4.46	-5.21	-0.39	-8.31	-1.86
Operating Profit Margin (%)	16.5%	-15.0%	7.8%	-4.5%	-42.2%	-64.1%	-101.0%	-3.9%	-232.0%	-159.0%
Other Income ⓘ	0.07	0.11	2.03	1.08	0.97	0.21	0.76	0.54	0.12	0.05
Interest ⓘ	2.74	3.10	1.60	2.22	1.55	0.31	0.23	0.27	2.13	0.79
Depreciation ⓘ	0.49	0	0.74	0.52	0.35	0.35	0.35	0.44	0.38	0.50
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	-0.54	-4.93	0.83	-2.51	-4.29	-4.91	-5.02	-0.57	-10.70	-3.09
Tax ⓘ	0	0	0	0	0	0	0.01	0.01	0.02	0.07
Profit After Tax	-0.54	-4.93	0.83	-2.51	-4.29	-4.91	-5.03	-0.57	-10.72	-3.16
PAT Margin (%)	-3.4%	-38.1%	5.7%	-13.2%	-53.9%	-70.5%	-98.4%	-5.7%	-300.0%	-270.0%
Adjusted EPS (₹)	-1.0	-9.1	1.5	-4.6	-7.9	-9.0	-9.3	-1.1	-19.8	-5.8
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Jun'99	Jun'00	Sep'01	Mar'03	Mar'04	Mar'05	Mar'06	Jun'07	Mar'08	Mar'09
Equity and Liabilities
Shareholders Fund	6.89	2.04	2.88	0.39	-3.90	-8.81	-13.84	11.69	0.96	-2.20
Share Capital ⓘ	5.43	5.43	5.43	5.43	5.43	5.43	5.43	5.43	5.43	5.43
Reserves ⓘ	1.47	-3.38	-2.55	-5.04	-9.33	-14.23	-19.26	6.26	-4.46	-7.62
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	12.97	18	17.62	21.43	20.70	21.02	21.22	10.25	12.43	13.53
Long Term Debt	12.97	18	17.62	21.43	20.70	21.02	21.22	10.25	12.43	13.53
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Trade Payables	2.98	3	3.14	2.81	2.12	2.06	1.64	1.98	1.96	1.85
Others Liabilities ⓘ	5.55	1.12	1.63	1.95	2.26	3.03	3.01	3.16	3.03	3.17
Total Liabilities ⓘ	28.39	24.16	25.27	26.58	21.18	17.31	12.03	27.08	18.39	16.35
Fixed Assets
Gross Block	7.12	7.19	7.45	7.57	7.56	7.54	7.55	20.88	20.46	20.47
Accumulated Depreciation	3.21	3.17	2.32	2.84	3.18	3.52	3.87	4.30	4.23	4.73
Net Fixed Assetsⓘ	3.91	4.02	5.12	4.73	4.37	4.03	3.68	16.58	16.23	15.75
CWIP ⓘ	0	0.06	0	0.02	0.03	0.03	0.03	0.03	0	0.03
Investmentsⓘ	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
Inventories	16.04	12.85	13.92	14.61	13.99	9.86	7.13	6.91	0.69	0.30
Trade Receivables	5.74	6.39	5.17	5.71	2.43	3.02	0.85	1.90	1.09	0.01
Cash Equivalents	1.76	0.45	0.40	0.94	0.12	0.07	0.05	1.37	0.08	0.02
Others Assetsⓘ	0.94	0.38	0.64	0.56	0.23	0.28	0.27	0.27	0.27	0.21
Total Assets ⓘ	28.39	24.16	25.27	26.58	21.18	17.31	12.03	27.08	18.39	16.35

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Jun'99	Jun'00	Sep'01	Mar'03	Mar'04	Mar'05	Mar'06	Jun'07	Mar'08
Cash Flow From Operating Activity ⓘ	-2.26	-2.78	0.51	-3.06	-0.09	-0.36	-0.21	12.29	-1.40
PBT ⓘ	-0.54	-4.99	-0.03	-2.51	-4.29	-4.91	-5.03	12.20	-10.73
Adjustment ⓘ	3.21	3.16	1.47	2.53	1.83	0.62	0.58	0.71	2.49
Changes in Working Capital ⓘ	-2.78	1.67	0.53	-1.1	3.82	4.16	4.39	-0.47	6.84
Tax Paid ⓘ	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ	-0.27	-0.11	-0.18	-0.12	-0.01	0	0	-0.01	0.01
Capex	-0.32	-0.16	-0.20	-0.15	-0.01	0	0	-0.01	0
Net Investments	-0.02	0	0	0	0	0	0	0	0
Others ⓘ	0.07	0.04	0.02	0.03	0	0	0	0	0.02
Cash Flow From Financing Activityⓘ	3.70	1.59	-0.39	3.72	-0.72	0.32	0.20	-10.97	0.09
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	0	0	0.12
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0
Others ⓘ	3.70	1.59	-0.39	3.72	-0.72	0.32	0.20	-10.97	-0.02
Net Cash Flow ⓘ	1.17	-1.31	-0.05	0.54	-0.82	-0.04	-0.02	1.32	-1.29

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Jun'99	Jun'00	Sep'01	Mar'03	Mar'04	Mar'05	Mar'06	Jun'07	Mar'08	Mar'09
Ratios
ROE (%)	-8.51	-117.33	33.93	-156.4	N/A	N/A	N/A	0	-169.47	N/A
ROCE (%)	12.54	-9.27	12.02	-1.36	N/A	N/A	N/A	-2.01	-48.5	N/A
Asset Turnover Ratio	0.66	0.53	0.63	0.76	0.35	0.38	0.37	0.56	0.17	0.07
PAT to CFO Conversion(x)	N/A	N/A	0.61	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	107	158	136	100	177	137	131	46	142	167
Inventory Days	313	377	315	263	621	600	572	236	361	150
Payable Days	255	152	192	127	212	111	229	164	153	1,328

Vysali Pharmaceuticals Ltd Stock News

Vysali Pharmaceuticals Ltd FAQs

What is the share price of Vysali Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Vysali Pharma on 01-Jan-1970 05:30 is ₹0.00.

What is the market cap of Vysali Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Vysali Pharma stood at ₹2.32.

What is the P/E ratio of Vysali Pharma?

The latest P/E ratio of Vysali Pharma as of 01-Jan-1970 05:30 is 0.00.

What is the P/B ratio of Vysali Pharma?

The latest P/B ratio of Vysali Pharma as of 01-Jan-1970 05:30 is -0.26.

What is the 52-week high and low of Vysali Pharma?

The 52-week high of Vysali Pharma is ₹0.00 and the 52-week low is ₹0.00.

What is the TTM revenue of Vysali Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Vysali Pharma is ₹1.17 ( Cr.) .

About Vysali Pharmaceuticals Ltd

Vysali Pharmaceuticals Limited incorporated in 1979 is an established Comapny manufacturing Active Pharmaceutical Ingredients of Sterile Injectable Penicillins and its manufacture all formulations from Penicillins to Cephalosporins with dedicated manufacturing facilities for beta lactam range of products. We export our products to various contries in Africa, European Traders, South America and Far East Asian countries. The company is also looking for association with established pharmaceutical Trading companies in various countries for marketing its products

Products off Vysali Pharmaceuticals includes, Sodampen, Crystacin, Gentrobex.

Type of pharmaceuticals

Other Pharmaceuticals (APIs), Penicillins, Polypeptides, Sulfonamides, Quinolones, Tetracyclines, OtherAminoglycosides, Chloramphenicols, Cephalosporins, Glycopeptides, Macrolides.

The registered office address of the company is situated at Seema, 41/427 Rajaji Road,Near Sun International,Ernakulam,Cochin 682035.